Learn languages naturally with fresh, real content!

Popular Topics
Explore By Region
AIM ImmunoTech's Ampligen drug in combo with Imfinzi shows promise in late-stage pancreatic cancer trial with positive results and tolerability.
AIM ImmunoTech has announced promising preliminary results from a Phase 1b/2 trial of its drug Ampligen in combination with AstraZeneca's Imfinzi for late-stage pancreatic cancer.
The therapy was well-tolerated, with no severe side effects noted.
Notably, two of three patients in the initial group reached the six-month stability assessment.
AIM ImmunoTech specializes in treatments for cancer, immune disorders, and viral diseases.
4 Articles
El medicamento Ampligen de AIM ImmunoTech en combinación con Imfinzi es prometedor en un ensayo de cáncer de páncreas en estadio tardío con resultados positivos y tolerabilidad.